Ann: Allowance of Canadian Patent on ATL1103 & Development Update, page-28

lol I think I will run with what the Chief said earlier......
Chief Investigator for this study, Dr Peter Trainer, Professor of Endocrinology, The Christie NHS Foundation Trust, UK, said: “The reduction in sIGF-I observed at the 400 mg dose in this small number of patients is most encouraging and supports the continuing recruitment of patients into the study and also indicates the potential to explore higher dosages and different dosing schedules in future clinical trials to optimize ATL1103 usage.”
Maybe as Sammy said it was to explore a higher dose as previously indicated ,either that or they might have found 2 really skinny acromegalics!
"International application PCT/AU2013/000095 has been lodged covering the use of ATL1103 in combination with the GHr antagonist Somavert, for the treatment of acromegaly and cancer."
I dont know but gee wiz that ties in nicely with Pfizer who some believe were the ones doing the due diligence previously (before talks were halted pending the results of the current phase2).